Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
China · Delayed Price · Currency is CNY 3.740
+0.090 (2.47%)
Feb 3, 2026, 3:04 PM CST
SHE:300267 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -308.33 | -373.37 | -195.32 | 45.94 | -791.2 | 192.31 |
Depreciation & Amortization | 197.36 | 197.36 | 204.29 | 176.49 | 197.09 | 191.36 |
Other Amortization | 3.45 | 3.45 | 7.81 | 5.28 | 2.26 | 0.9 |
Loss (Gain) From Sale of Assets | -0.2 | -0.2 | -8.8 | -0.05 | -0.23 | -0.22 |
Asset Writedown & Restructuring Costs | 237.41 | 237.41 | 12.91 | 0 | 703.18 | 2.55 |
Loss (Gain) From Sale of Investments | 55.58 | 55.58 | 8.53 | -18.88 | -18.84 | -124.13 |
Provision & Write-off of Bad Debts | -1.53 | -1.53 | 62.85 | 7.56 | -11.54 | 20.73 |
Other Operating Activities | 92.03 | 21.2 | 29.46 | 1.73 | 208.2 | 36.13 |
Change in Accounts Receivable | -21.89 | -21.89 | -19.96 | -9.11 | 125.94 | -189.5 |
Change in Inventory | 66.64 | 66.64 | 46.97 | -111.76 | -161 | 57 |
Change in Accounts Payable | -35.61 | -35.61 | 8.58 | 76.47 | 35.93 | -93.44 |
Change in Other Net Operating Assets | 15.35 | 15.35 | -18.47 | 133.6 | -137.98 | 22.22 |
Operating Cash Flow | 302.56 | 166.69 | 148.42 | 281.02 | 92.68 | 113.49 |
Operating Cash Flow Growth | 22.56% | 12.31% | -47.19% | 203.20% | -18.33% | -74.54% |
Capital Expenditures | -139.07 | -195.6 | -238.19 | -173.49 | -349.33 | -595.89 |
Sale of Property, Plant & Equipment | 1.36 | 0.18 | 20.11 | 0.4 | 1.24 | 0.07 |
Cash Acquisitions | - | - | - | - | -60.55 | -3.72 |
Divestitures | - | - | - | 1.42 | 3.31 | 100.42 |
Investment in Securities | -105 | -119.77 | 100.35 | -100 | 354.93 | -398 |
Other Investing Activities | -6.24 | -6.97 | 12.81 | 13.09 | 17.22 | 19.49 |
Investing Cash Flow | -248.95 | -322.15 | -104.92 | -258.58 | -33.18 | -877.63 |
Short-Term Debt Issued | - | 546.08 | 341 | 376.75 | 396 | 820 |
Total Debt Issued | 702.37 | 546.08 | 341 | 376.75 | 396 | 820 |
Short-Term Debt Repaid | - | -401 | -380.13 | -246 | -613 | -377 |
Long-Term Debt Repaid | - | -5.52 | -3.36 | -5.07 | -3.32 | - |
Total Debt Repaid | -605.22 | -406.52 | -383.5 | -251.07 | -616.32 | -377 |
Net Debt Issued (Repaid) | 97.15 | 139.56 | -42.5 | 125.68 | -220.32 | 443 |
Issuance of Common Stock | - | - | 30.59 | - | - | 20 |
Repurchase of Common Stock | - | - | - | - | - | -83.94 |
Common Dividends Paid | -10.52 | -8.42 | -70.1 | -4.73 | -114.92 | -41.58 |
Other Financing Activities | -116.79 | 10 | -84 | -130.33 | -0.01 | 1 |
Financing Cash Flow | -30.17 | 141.14 | -166.01 | -9.37 | -335.25 | 338.47 |
Foreign Exchange Rate Adjustments | 0.79 | -6.41 | 0.2 | 18.3 | -2.98 | -9.01 |
Net Cash Flow | 24.23 | -20.73 | -122.3 | 31.37 | -278.72 | -434.68 |
Free Cash Flow | 163.49 | -28.91 | -89.77 | 107.53 | -256.65 | -482.4 |
Free Cash Flow Growth | 633.26% | - | - | - | - | - |
Free Cash Flow Margin | 12.66% | -2.54% | -5.03% | 5.75% | -11.48% | -20.25% |
Free Cash Flow Per Share | 0.08 | -0.01 | -0.04 | 0.05 | -0.12 | -0.23 |
Cash Income Tax Paid | 46.56 | 43.32 | 58.01 | -3.22 | 70.54 | 89.72 |
Levered Free Cash Flow | -52.24 | -14.38 | 15.77 | 36.83 | -65.62 | -338.68 |
Unlevered Free Cash Flow | -46.67 | -8.95 | 19.94 | 40.48 | -59.82 | -329.09 |
Change in Working Capital | 26.79 | 26.79 | 26.7 | 62.96 | -196.24 | -206.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.